Skip to main content
. 2021 Sep 16;28(1):116–119. doi: 10.1016/j.jiac.2021.09.009

Table 1.

Participants’ characteristics and reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine.

No. (%)

Dose 1 (n = 3254) Dose 2 (n = 3165)
No. of recipients 3381 3354
No. of respondents 3254 (96.2) 3165 (94.4)
Demographic characteristics .. ..
Age Groups
 ≤29 1178 (36.2) 1132 (35.8)
 30–39 953 (29.3) 926 (29.3)
 40–49 632 (19.4) 624 (19.7)
 50–59 329 (10.1) 324 (10.2)
 60–69 138 (4.2) 137 (4.3)
 ≥70 24 (0.8) 22 (0.7)
Sex .. ..
 male 1116 (34.3) 1091 (34.5)
 female 2138 (65.7) 2074 (65.5)
Occupation
 doctor 926 (28.5) 899 (28.4)
 nurse 1162 (35.7) 1129 (35.7)
 pharmacist 100 (3.1) 100 (3.2)
 administrative staff 1066 (32.8) 1037 (32.8)
Reactogenicity .. ..
Any 3165 (97.3) 3077 (97.2)
Injection site reactions (any) 2972 (91.3) 2915 (92.1)
 pain 2908 (89.4) 2736 (87.3)
 swelling 1001 (30.8) 1359 (42.9)
 burning sensation 930 (28.6) 1194 (37.7)
 redness 494 (15.2) 840 (26.5)
 induration 545 (16.7) 606 (19.1)
 itching 327 (10.0) 514 (16.2)
Systemic reactions (any) 2445 (75.1) 2748 (86.8)
 fatigue 901 (27.7) 2304 (72.8)
 myalgia (muscle ache) 2132 (65.5) 2035 (64.3)
 headache 463 (14.2) 1447 (45.7)
 fever 95 (2.9) 1354 (42.8)
 - low-grade fever (≥37.5°C, but < 38.0°C) 70/95 (73.7) 757/1354 (55.9)
 - high-grade fever (≥38.0°C) 25/95 (26.3) 597/1354 (44.1)
 chills 119 (3.7) 1180 (37.3)
 joint pain 198 (6.1) 1092 (34.5)
 nasal discharge 49 (1.5) 69 (2.2)
 Anaphylaxis 1 (0.03) 1 (0.03)
Absence from work (no. of days) ..
 no absence 3183 (97.8) 2555 (80.7)
 1 day 48 (1.5) 461 (14.6)
 2–3 days 6 (0.2) 137 (4.3)
 4–5 days 9 (0.3) 6 (0.2)
 ≥6 days 8 (0.2) 6 (0.2)